Moreover, many studies have suggested that eIF3a affects patient prognosis and treatment responses; for example, patients with cancer presenting high eIF3a levels experience better relapse-free and overall survival than those with low eIF3a expression (Dellas et al., 1998; Chen and Burger, 1999). The gene discussed is EIF3A; the disease is cancer.